You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK)公布自研藥物AK120 Ib期美國臨床試驗獲批
阿思達克 12-01 08:56
康方生物(09926.HK)表示,公司自主研發的IL-4R單克隆抗體注射液(研發代號:AK120)獲得美國食品藥品管理局允許在美國開展治療中重度特應性皮炎的Ib期臨床研究。

AK120已在新西蘭完成健康受試者單次皮下注射劑量遞增的安全性、耐受性及藥代動力學臨床研究,正在新西蘭和澳大利亞開展對中重度特應性皮炎受試者多次皮下注射劑量遞增Ib期臨床研究。

AK120是公司自主研發的靶向IL-4R的新型自身免疫疾病治療藥物,擬用於治療特應性皮炎、哮喘等過敏性疾病。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account